Diagnostic potential of circulating natriuretic peptides in chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 21, Issue 2, 2006, Pages 402-410

  Mark, Patrick B ^a,b   Stewart, Graham A ^b,c   Gansevoort, Ron T ^b,d   Petrie, Colin J ^b   McDonagh, Theresa A ^b,e   Dargie, Henry J ^b   Rodger, R Stuart C ^a   Jardine, Alan G ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c NINEWELLS HOSPITAL   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Atrial natriuretic peptide; Brain natriuretic peptide; Cardiomyopathy; Chronic renal failure; Left ventricular hypertrophy

Indexed keywords

ALBUMIN; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; NATRIURETIC FACTOR;

ADULT; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CHRONIC KIDNEY DISEASE; CONFOUNDING VARIABLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADULT; ATRIAL NATRIURETIC FACTOR; CARDIOMYOPATHIES; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN;

EID: 31544458419     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi187     Document Type: Article

References (20)

1. Cowie MR, Struthers AD, Wood DA et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. The Lancet 1997; 350: 1349-1353
2. McDonagh TA, Robb SD, Murdoch DR et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13
3. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147-152
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
5. Reis SE, Olson MB, Fried L et al. Mild renal insufficiency is associated with angiographic coronary artery disease in women. Circulation 2002; 105: 2826-2829
6. Foley RN, Parfrey PS, Harnett JD et al. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995; 5: 2024-2031
7. Stewart GA, Gansevoort RT, Mark P et al. Electrocardiographic abnormalities and uraemic cardiomyopathy. Kidney Int 2004; 67: 217-226
8. Takami Y, Horio T, Iwashima Y et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis 2004; 44: 420-428
9. Tikkanen I, Metsarinne K, Gronhagen-Riska C, Fyhrquist F. Plasma level of atrial natriuretic peptide as an indicator of increased cardiac load in uremic patients. Clin Nephrol 1990; 34: 167-172
10. Mallamaci F, Zoccali C, Tripepi G et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001; 59: 1559-1566
11. Zoccali C, Mallamaci F, Benedetto FA et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001; 12: 1508-1515
12. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083
13. Northridge DB, Jamieson MP, Jardine AG et al. Pulmonary extraction and left atrial secretion of atrial natriuretic factor during cardiopulmonary bypass surgery. Am Heart J 1992; 123: 698-703
14. Troughton RW, Frampton CM, Yandle TG et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-1130
15. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004-1009
16. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339: 321-328
17. McCullough PA, Duc P, Omland T et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41: 571-579
18. Totsune K, Takahashi K, Satoh F et al. Urinary immunoreactive brain natriuretic peptide in patients with renal disease. Regul Pept 1996; 63: 141-147
19. DeFilippi CR, Fink JC, Nass CM, Chen H, Christenson R. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 2005; 46: 35-44
20. van der Meer P, Voors AA, Lipsic E et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004; 44: 63-67